These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31589620)

  • 21. Clinical Performance of Nonvitamin K Antagonist Oral Anticoagulants in Real-World Obese Patients with Atrial Fibrillation.
    Russo V; Bottino R; Rago A; Papa AA; Liccardo B; D'Onofrio A; Golino P; Nigro G
    Semin Thromb Hemost; 2020 Nov; 46(8):970-976. PubMed ID: 33105504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation.
    Fosbøl EL; Vinding NE; Lamberts M; Staerk L; Gundlund A; Gadsbøll K; Køber L; Gislason GH; Olesen JB
    Europace; 2018 Jun; 20(6):e78-e86. PubMed ID: 28666358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial.
    Joosten LPT; van Doorn S; van de Ven PM; Köhlen BTG; Nierman MC; Koek HL; Hemels MEW; Huisman MV; Kruip M; Faber LM; Wiersma NM; Buding WF; Fijnheer R; Adriaansen HJ; Roes KC; Hoes AW; Rutten FH; Geersing GJ
    Circulation; 2024 Jan; 149(4):279-289. PubMed ID: 37634130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry.
    Beyer-Westendorf J; Gelbricht V; Förster K; Ebertz F; Röllig D; Schreier T; Tittl L; Thieme C; Hänsel U; Köhler C; Werth S; Kuhlisch E; Stange T; Röder I; Weiss N
    Br J Clin Pharmacol; 2014 Oct; 78(4):908-17. PubMed ID: 24697922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists.
    Sørensen R; Jamie Nielsen B; Langtved Pallisgaard J; Ji-Young Lee C; Torp-Pedersen C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jul; 3(3):151-156. PubMed ID: 28158553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use and Outcomes of Triple Antithrombotic Therapy with Non-Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Casamira N; García-Camarero T; Montoro-Ronsano JB; Veiga G; Del Blanco BG; De La Torre JM; Gordon B; García-Dorado D; Sambola A
    Am J Med Sci; 2019 Aug; 358(2):95-103. PubMed ID: 31176420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of patient selection in clinical trials: application of ROCKET AF and ARISTOTLE criteria in GARFIELD-AF.
    Himmelreich JCL; Virdone S; Camm J; Pieper K; Harskamp RE; Oto A; Jacobson BF; Sawhney JPS; Lim TW; Gibbs H; Goto S; Haas S; Fox KAA; Jansky P; Verheugt F; Kakkar AK;
    Open Heart; 2024 Jul; 11(2):. PubMed ID: 38955399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.
    Moreno-Arribas J; Bertomeu-González V; Anguita-Sanchez M; Cequier Á; Muñiz J; Castillo J; Sanchis J; Roldán I; Marín F; Bertomeu-Martínez V;
    J Cardiovasc Pharmacol Ther; 2016 Mar; 21(2):150-6. PubMed ID: 26229096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Real-world adherence to oral anticoagulants in atrial fibrillation].
    Simonyi G; Paksy A; Várnai R; Medvegy M
    Orv Hetil; 2020 May; 161(20):839-845. PubMed ID: 32364687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Vitamin K antagonists : Is their prescription really "medical malpractice" today?].
    Rafflenbeul E; Müller-Ehmsen J
    Internist (Berl); 2017 Jan; 58(1):90-99. PubMed ID: 28058458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016.
    Maura G; Billionnet C; Drouin J; Weill A; Neumann A; Pariente A
    BMJ Open; 2019 Apr; 9(4):e026645. PubMed ID: 31005934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Oral anticoagulation in atrial fibrillation: differential therapy with non vitamin K antagonist oral anticoagulants (NOAC) and vitamin K antagonists (VKA)].
    Sucker C; Litmathe J; Berthold HK
    MMW Fortschr Med; 2019 Oct; 161(Suppl 6):15-23. PubMed ID: 31587168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
    Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
    Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Network meta-analysis of efficacy and safety of competitive oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation.
    Li PJ; Xiao J; Yang Q; Feng Y; Wang T; Liu GJ; Liang ZA
    J Interv Card Electrophysiol; 2016 Sep; 46(3):213-24. PubMed ID: 27001171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study.
    Bouillon K; Bertrand M; Maura G; Blotière PO; Ricordeau P; Zureik M
    Lancet Haematol; 2015 Apr; 2(4):e150-9. PubMed ID: 26687957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial.
    De Caterina R; John Camm A
    Europace; 2016 Jan; 18(1):6-11. PubMed ID: 26450845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation.
    Lee SR; Lee YS; Park JS; Cha MJ; Kim TH; Park J; Park JK; Lee JM; Kang KW; Shim J; Uhm JS; Kim J; Kim C; Kim JB; Park HW; Joung B; Choi EK
    Yonsei Med J; 2019 Mar; 60(3):277-284. PubMed ID: 30799590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-persistence risk and health care resource utilization of Italian patients with non-valvular atrial fibrillation.
    Cataldo N; Pegoraro V; Ripellino C; Bertasi V; Di Turi R; Pastorello M; Gambera M
    Recenti Prog Med; 2018 Feb; 109(2):113-121. PubMed ID: 29493635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
    Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.